US › Healthcare

Alpha Tau Medical Ltd (DRTS)

US · Healthcare · Biotechnology

$15.49+2.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-45.8M

EPS

$-0.50

EPS estimate

$-0.14

EPS came in at -0.50 against a street estimate of -0.14 — a miss of 257.1%.

Key statistics

Market cap

$1.33B

Forward P/E

0.0

P/B

30.29

Book value

$0.48

EPS (TTM)

$-1.04

52-week high

$15.17

52-week low

$3.43

50-day MA

$13.51

200-day MA

$9.00

Beta

1.21

Analyst view

Analysts rate Alpha Tau Medical Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $17.80.

Shareholding

Insiders

30.50%

Institutions

9.07%

Largest institutional holders

Fund	Stake
Gem Investment Advisors, LLC	1.55%
HighTower Advisors, LLC	0.95%
Aquamarine Financial (Cayman) Ltd	0.78%
Pier Capital, LLC	0.75%
Apella Capital, LLC	0.41%
ARK Investment Management LLC	0.32%
UBS Group AG	0.31%
Mariner Wealth Advisors LLC	0.16%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alpha Tau Medical Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.